US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
4 deals · US$11bndisclosed · Dermatology · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2026 | Apogee Therapeutics | – | AbbVie | Acquisition | Pending | 10,900.0 | Biotech+2 | Goldman Sachs (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Paul, Weiss (buy-side)Morgan Stanley (buy-side) |
| Jun 2026 | Obagi Medical dermatological skincare and aesthetics business | Waldencast | Bridgepoint | Asset sale | Announced | – | Skin Care+2 | LazardLatham & Watkins (buy-side) |
| May 2026 | Replay | – | LEO Pharma | Acquisition | Announced | 50.0 | Biotech+2 | Latham & Watkins (buy-side) |
| Feb 2026 | Wilmington Dermatology Center | – | DermCare Management | Acquisition | Completed | – | Dermatology+2 | Capstone Partners (sell-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built